Shree Ganesh Remedies Ltd. · BSE:SGRL
Shree Ganesh Remedies — Q2 & H1 FY26 Earnings Presentation
37 slides from Shree Ganesh Remedies's earnings presentation, Nov 7, 2025
Slide 1: Covering letter to BSE
November 07, 2025 To, Listing Department, The BSE Limited, Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai - 400001. Scrip Code: 540737 Dear Sir(s)/Ma’am, Sub: Investor Presentation With reference to the captioned subject, we enclose herewith the Investor Presentation with respect to Unaudited Finan
Slide 2: Investor Presentation Q2 & H1FY26
Investor Presentation Q2 & H1FY26 Innovate. React. Transform.
Slide 3: Inside the Presentation
Inside the 19 Dahej Land Acquisition Setting the Stage for Large Scale Projects Forward Presentation 20 Driving Innovation Through Strategic R&D Investments 21 State-of-the-Art R&D Infrastructure Looking 22 State-of-the-Art Pilot Infrastructure Statement In so far as forecasts or 23 Accreditations t
Slide 4: Quarterly Highlights
Quarterly Highlights Management Commentary 04 P&L Summary 05 Balance Sheet Summary 06 Cash Flow Summary 07 04
Slide 5: Management Commentary
Management Commentary QUARTERLY HIGHLIGHTS “In line with our expectations, SGRL delivered sequential Work on Block 7 is progressing as planned, with the plant growth in Q2FY26, reflecting the company’s historically expected to be operational and begin commercial production stronger performance in th
Slide 6: P&L Summary
P&L Summary QUARTERLY HIGHLIGHTS YoY Change -6% -15% -23% Revenue EBITDA PAT YoY QoQ YoY PARTICULARS ( ₹ I N C R O R E S ) Q2FY25 Q1FY26 Q2FY26 H1FY25 H1FY26 Change Change Change Revenue from Operations 32.33 24.67 30.32 -6% 23% 57.11 54.98 -4% Total Income 32.52 25.33 31.00 -5% 22% 57.84 56.33 -3%
Slide 7: Balance Sheet Summary
Balance Sheet Summary QUARTERLY HIGHLIGHTS PARTICULARS ( ₹ I N C R O R E S ) FY25 H1FY26 Shareholders' Funds 145.19 153.57 Non-Current Liabilities 30.60 29.33 Long Term Borrowings 29.48 27.73 Current Liabilities 16.18 21.25 Short Term Borrowings 8.76 9.65 Trade Payables 5.97 9.51 Total Equity and Li
Slide 8: Cash Flow Summary
Cash Flow Summary QUARTERLY HIGHLIGHTS PARTICULARS ( ₹ I N C R O R E S ) H1FY25 H1FY26 Cash from Operating Activities 13.64 17.66 Cash from Investing Activities -10.35 -8.23 Cash from Financing Activities -4.90 -5.73 Net Cash Flow -1.61 3.70 Cash at the Beginning of Year 16.20 11.12 Cash at the End
Slide 9: About the Business
About the Business Excellence in Complex Chemistry 09 Unparalleled Expertise in Advanced Chemical Synthesis 10 Unmatched Technology Prowess In Complex Chemical Reactions 12 Tailored Solutions Through Mastered Chemistry and Technology 13 Strategic Product Selection Criteria 14 Our Evolving Business M
Slide 10: Excellence in Complex Chemistry
Excellence in Complex Chemistry ABOUT THE COMPANY Established Expertise Strategic Expansions Over 20 years of excellence in chemical Continuous investments in new manufacturing manufacturing, specialising in pharmaceutical blocks and R&D centers to enhance production intermediates and speciality che
Slide 11: Unparalleled Expertise in Advanced Chemical Synthesis
Unparalleled ABOUT THE COMPANY Core Strengths in Mastered Chemistries Expertise in Our company excels in the following core chemistries, with dedicated manufacturing blocks for each: Advanced 1. Halogenation Chemical • Chlorination: Using Thionyl Chloride, Sulphuryl Chloride, Oxalyl Chloride, Mesyl
Slide 12: Unparalleled Expertise in Advanced Chemical Synthesis (Continued)
ABOUT THE COMPANY Unparalleled Expertise in Advanced Chemical Synthesis (Continued) Additional Chemistries Other Reaction Capabilities While we currently do not have dedicated Heterocycle Synthesis 1 blocks for the following chemistries, we have Nitration 2 established a strong foothold and are eval
Slide 13: Unmatched Technology Prowess in Complex Chemical Reactions
Unmatched ABOUT THE COMPANY Technology Prowess Key Technological Capabilities In Complex Chemical Liquid-Gas Reaction: Expertise in managing reactions involving both liquid and 1 gas phases, ensuring optimal reaction conditions and high yields. High-Pressure Reaction: Proficiency in conducting react
Slide 14: Tailored Solutions Through Mastered Chemistry and Technology
Tailored Solutions Through ABOUT THE COMPANY Mastered Chemistry and Technology Products by chemistry Industries Catered Chloro-Alkyl Amines HCl Salts Human and Veterinary Health Cyclopropane Derivatives Cyclobutane Derivatives Agrochemical Industry Carboxylic Acids & Acid Chlorides Aliphatic Chlorid
Slide 15: Strategic Product Selection Criteria
Strategic ABOUT THE COMPANY Product Chemistry Skillset The product must fall Selection within the chemistry skills Technology Skillset Margin Profile we have mastered. We must be capable of The product must meet our handling the complex internal benchmarks for Criteria processes involved, or we sust
Slide 16: Our Evolving Business Model
Our Evolving Business Model ABOUT THE COMPANY Inception Inception Pharmaceutical Intermediates Speciality and Fine Chemicals Since Company’s inception in 2004 Entered in 2010 Focus Focus Intermediates for Off-patent and generic drugs requiring control Moving towards patented molecules and customer s
Slide 17: Collaborating With Industry Leaders
Collaborating With Industry Leaders ABOUT THE COMPANY 16 Shree Ganesh Remedies Limited
Slide 18: Ankleshwar Site Expansion Fuelling Our Growth Strategy
Ankleshwar Site ABOUT THE COMPANY Expansion Fuelling Our Growth Strategy Unit 1 Production Blocks • Currently 7 functional blocks • Block 8 added in FY24 • Block 7: To be commissioned in H1FY27 Block 8 • On going CAPEX for Plant 7 • Commissioning of all new Pilot Plant: implementing Automation Capab
Slide 19: Infrastructure at Ankleshwar Site
Infrastructure at ABOUT THE COMPANY Ankleshwar Site 35 28 Glass Lined Reactors Stainless Steel Reactors 1000 to 25,000 Ltr 1000 to 15,000 Ltr *2 cryogenic (-30 Deg C) *1 cryogenic (-40 Deg C) 3 9 8 4 Autoclave Reactors Dryers Distillation Setup Warehouse 2000 Ltr 1000 to 2,500 Ltr Upto 70 Stages Upt
Slide 20: Dahej Land Acquisition Setting the Stage for Large Scale Projects
Dahej Land Acquisition ABOUT THE COMPANY Setting the Stage for Large Scale Projects Site Development • Initiated the construction of common infrastructure, utilities, and warehousing facilities Land Expansion Strategic Use Acquired 40,554 sq m land • Dahej site to host projects with large corporates
Slide 21: Driving Innovation Through Strategic R&D Investments
Driving Innovation ABOUT THE COMPANY R&D Lab Recognition Through Strategic Recognised by DSIR (Department of Scientific and Industrial Research), Central Government R&D Investments R&D and Process Team Composition 40 Total Team Members Global Expansion Exploring the setup of R&D facilities in foreig
Slide 22: State-of-the-Art R&D Infrastructure
State-of-the-Art R&D Infrastructure ABOUT THE COMPANY Key Facilities Advanced Analytical Labs Equipped with cutting-edge instruments for precise analysis Pilot Plants For scale-up studies and process optimisation Dedicated Synthesis Labs For novel compound development High-Performance Computing (HPC
Slide 23: State-of-the-Art Pilot Infrastructure
State-of-the-Art Pilot Infrastructure ABOUT THE COMPANY As a critical enabler of our growth strategy, our Pilot Plant stands at the forefront of innovation, bridging the gap between research and commercial production. Vital Role in R&D and Scale-Up Expansion and Enhanced • Accelerates the transition
Slide 24: Accreditations that Speak to Our Comprehensive Standards
Accreditations that Speak to ABOUT THE COMPANY Our Comprehensive Standards Indian GMP Certified ISO 9001:2015 Certified ISO 14001:2015 Certified ISO 45001:2018 Manufacturing Facility (Bureau Veritas) (Bureau Veritas) Certified (CCPL) DSIR Recognised Bronze Certified by ISO 14064:3 Certified Halal In
Slide 25: Driving Innovation and Growth
Driving Innovation and Growth ABOUT THE COMPANY Chandu Kothia Gunjan Kothia Parth Kothia Founding Promoter, Promoter, Promoter, Managing Director Head of Business Development & Innovation Whole Time Director, CFO Qualifications: Master of Science & Qualifications: BE in Chemical Engineering Qualific
Slide 26: Ensuring Health and Safety
Ensuring Health and Safety ABOUT THE COMPANY Technical Personal Protection Organisational Health Measures Equipment Measures Check Closed charging and Working clothes with HAZOP compatible study Regular health check-ups discharging systems glasses and gloves on raw materials and finished products He
Slide 27: Protecting the Environment With Sustainable Practices
Protecting the ABOUT THE COMPANY Environment With Sustainable Practices Conversion of In-house High- Biological Implemented a 2.5 flue gases to by- wastewater temperature waste water MW solar power products for treatment for incinerator for treatment park, expected to environmental recycling of toxi
Slide 28: Financial Highlights
Financial Highlights 5 Year Summary 28 Key Ratios 29 P&L Summary 30 Balance Sheet Summary 31 Cash Flow Summary 32 02
Slide 29: 5 Year Summary
5 Year Summary FINANCIAL HIGHLIGHTS Revenue from Operations Profit After Tax EBITDA & EBITDA Margins EPS (₹ IN CRORES) (₹ IN CRORES) (₹ IN CRORES & IN %) (IN ₹) 24% 22% 25 33.2% 36.1% 45.00 40.0% CAGR CAGR 40.00 35.0% 20 39.21 35.00 27.8% 25.1% 25.7% 30.0% 108.60 23.10 17.98 30.00 25.0% 15 25.00 20.
Slide 30: Key Ratios
Key Ratios FINANCIAL HIGHLIGHTS ROE ROCE Equity & Debt to Equity Ratio Cash from Operating Activities (IN %) (IN %) (₹ IN CRORES & IN TIMES) (₹ IN CRORES) 0.38 35 160.00 0 30 140.00 0 30.66 145.19 120.00 0 25 100.00 0 0.26 20 15.9% 80.00 0.25 0 15 19.0% 60.00 0 61.57 10 50.00 3.31 40.00 0 122.11 19.
Slide 31: P&L Summary
P&L Summary FINANCIAL HIGHLIGHTS CAGR 22% 30% 24% (FY21-25) Revenue EBITDA PAT PARTICULARS ( ₹ I N C R O R E S ) FY21 FY22 FY23 FY24 FY25 Revenue from Operations 49.08 71.29 91.36 125.90 108.60 Total Income 51.18 74.86 92.07 128.96 112.33 Operating Expenses 35.43 53.37 67.92 84.09 69.38 EBITDA (Excl
Slide 32: Balance Sheet Summary
Balance Sheet Summary FINANCIAL HIGHLIGHTS PARTICULARS ( ₹ I N C R O R E S ) FY21 FY22 FY23 FY24 FY25 Shareholders' Funds 50.00 61.57 87.20 122.11 145.19 Non-Current Liabilities 0.41 0.40 30.66 30.16 30.60 Long Term Borrowings 0.00 0.00 30.44 29.12 29.48 Current Liabilities 10.19 15.04 20.11 18.68 1
Slide 33: Cash Flow Summary
Cash Flow Summary FINANCIAL HIGHLIGHTS PARTICULARS ( ₹ I N C R O R E S ) FY21 FY22 FY23 FY24 FY25 Cash from Operating Activities 3.31 13.42 17.10 30.45 30.66 Cash from Investing Activities (0.94) (11.91) (51.09) (33.09) (35.66) Cash from Financing Activities (0.66) (1.09) 38.66 9.85 (1.06) Net Cash
Slide 34: Investment Merits
Investment Merits Investment Case 34 03
Slide 35: Investment Case
Investment Case INVESTMENT MERITS Lean Balance Experienced Increasing Focus Available Land for Humongous Sheet: Management at on Complex Further Capacity Addressable The company the Helm: Molecules and Expansions: Opportunity Size: maintains a strong Led by a seasoned Niche Specialty With ample land
Slide 36: Market Statistics
Market Statistics Shareholding Pattern CURRENT MARKET PRICE ₹ 575.85 52 WEEK HIGH/LOW ₹ 950.00 / 560.00 MARKET CAPITALIZATION ₹ 739.10 Cr SHARES OUTSTANDING 1.28 Cr Promoter 72.80% BSE SCRIP CODE 540737 Public 27.20% Shareholding Data as on 30th September 2025 Market Price Data as on 7st November 20
Slide 37: Contact Us
Contact Us Shree Ganesh Remedies Limited Headquarters: Plot No. 6002, 6003, 6011 & 6012, GIDC Estate, Ankleshwar, Gujarat India – 393002 Aditya Patel Abhishek Mehra Company Secretary Investor Relations Advisors Shree Ganesh Remedies Limited TIL Advisors Private Limited [email protected] a
Shree Ganesh Remedies — Q2 & H1 FY26 Earnings Presentation on 6ix